Literature DB >> 18538839

Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.

Rafael Santana-Davila1, Ayalew Tefferi, Shernan G Holtan, Rhett P Ketterling, Gordon W Dewald, Ryan A Knudson, David P Steensma, Dong Chen, James D Hoyer, Curtis A Hanson.   

Abstract

Among 23 cases of myeloproliferative neoplasms (MPNs) with an associated del(5q) seen at our institution, 14 (61%) fulfilled diagnostic criteria for primary myelofibrosis (PMF). Other diagnoses included polycythemia vera (PV; n=2), essential thrombocythemia (ET; n=1), post-ET myelofibrosis (n=1), systemic mastocytosis (SM; n=1), and MPN, unclassifiable (n=4). Compared to their del(5q)-negative counterparts, del(5q)-positive PMF cases were significantly more anemic (p<0.001) and thrombocytopenic (p<0.001). However, survival and leukemic transformation rates appear to be similar between the two groups. del(5q)-positive PMF was histologically characterized by a mixture of both small and monolobated megakaryocytes as well as large and bizarre megakaryocytes. When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology.

Entities:  

Mesh:

Year:  2008        PMID: 18538839     DOI: 10.1016/j.leukres.2008.04.022

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

Authors:  Koichi Takahashi; Jorge Cortes; Sherry Pierce; Lynne Abruzzo; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-02-04       Impact factor: 3.156

3.  Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features?

Authors:  Valentina F I Sangiorgio; Julia T Geyer; Elizabeth Margolskee; Mustafa Al-Kawaaz; Susan Mathew; Wayne Tam; Attilio Orazi
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

4.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

5.  Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy.

Authors:  Antonella Vaccarino; Irene Dogliotti; Fabio Marletto; Andrea Demarchi; Mario Bazzan
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

6.  Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature.

Authors:  Jackline P Ayres-Silva; Martin H Bonamino; Maria E Gouveia; Barbara C R Monte-Mor; Diego F Coutinho; Adelmo H Daumas; Cristiana Solza; Esteban Braggio; Ilana Renault Zalcberg
Journal:  Front Oncol       Date:  2018-02-19       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.